What You Should Know:
– Dandelion Health, a leader in real-world data (RWD) and clinical AI, has unveiled the industry’s first-ever multimodal GLP-1 data library.
– The multimodal GLP-1 data library empowers researchers and life sciences companies to unlock deeper insights into the use of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for precision medicine.
Unprecedented Depth of Real-World Data
Gathered from Dandelion’s network of collaborating medical centers, the GLP-1 data library offers a comprehensive view of millions of patient journeys. Notably, this includes data for over 200,000 patients using GLP-1 medications. The library goes beyond basic demographics, incorporating the entire patient experience with high fidelity. This includes structured data from electronic health records (EHRs) alongside all raw clinical data generated during care (imaging scans, ECG waveforms, and clinician notes). By combining these diverse data sources, Dandelion’s library offers unparalleled insights into how patients respond to GLP-1 treatments.
Unlocking the Potential of GLP-1 Treatments
Dandelion Health is a healthcare technology company at the forefront of innovation. Their RWD and clinical AI platform empowers researchers with rich, multimodal patient data, accelerating advancements in AI, medical devices, and life sciences. Life sciences companies and researchers can leverage the GLP-1 data library for a multitude of purposes, including:
- Precision Measurement of Treatment Efficacy: Go beyond weight loss (measured by BMI) and utilize biomarkers from body scans to evaluate the true impact of treatment on body composition, including muscle and bone preservation.
- Real-World Treatment Comparisons: Compare the effectiveness of different GLP-1 drugs across various real-world metrics, providing valuable insights beyond traditional clinical trials.
- Uncovering Hidden Benefits: Explore the potential of GLP-1 medications for treating conditions beyond their current uses, identifying secondary benefits through additional data analysis.
- Mitigating Treatment Risks: Quantify and understand potential side effects associated with GLP-1 drugs.
- Precision Medicine Advancements: Develop tools to identify patients who may not respond well to certain GLP-1 treatments and match patients to the most effective treatment plans.
Extracting Value from Unstructured Data
Dandelion highlights that roughly 80% of medical data remains trapped in silos or buried within unstructured formats like clinician notes or imaging data. Their platform utilizes advanced AI algorithms to unlock this valuable information, transforming unstructured data into a powerful research tool.
Supporting Cutting-Edge Research
Dandelion is actively collaborating with researchers to leverage the GLP-1 data library for groundbreaking discoveries. One example involves an academic medical center developing an AI algorithm to analyze abdominal CT scans and quantify fat loss and muscle/bone preservation with GLP-1 treatments. This offers a more holistic picture of treatment efficacy compared to solely focusing on weight loss.
Proprietary Research and Future Publications
Dandelion has also conducted its own research using the library’s data. This research has explored:
- The effectiveness of GLP-1 drugs across diverse patient populations.
- The relationship between treatment duration and patient outcomes.
- Potential impacts of GLP-1 medications on other health conditions, suggesting new treatment applications.
Dandelion plans to publish these findings in a scientific preprint during Q2 2024.
“Our GLP-1 dataset will help cardiometabolic disease enter its precision medicine era. While the past few years have produced great advancements in obesity care, there is still a wide gap between cardiometabolic care today and the high-innovation, high-investment, and deeply personalized care paradigms we see in immunology and oncology,” said Elliott Green, Co-founder and CEO of Dandelion Health. “What got those markets to where they are today was data — data that revealed underlying mechanisms of disease, how individuals’ diseases look different, and consequently, how they might respond to therapy differently.”